Story perspectives

Trump's 100% Tariff Threat Spurs $350B Pharma Investment

10/1/2025

Summary

Story summary

President Trump will impose a 100% tariff on branded pharmaceuticals starting October 1, 2025, unless companies invest in U.S. manufacturing.
Pfizer aims to reduce drug costs and invest $70 billion domestically, supporting Trump's focus on local production.
The auto industry disputes claims of new factory construction, stating companies are retooling existing plants.
Major pharmaceutical firms, including Johnson & Johnson and Eli Lilly, have pledged over $350 billion to U.S. manufacturing due to tariff threats.
Critics caution that immediate tariffs may harm smaller biotech firms and stifle innovation, potentially aiding China's biotech sector.

History

Historical Context

The Bayh-Dole Act of 1980 enabled U.S. universities and small businesses to patent inventions from federally funded research, significantly enhancing domestic innovation. In response to tariff threats, pharmaceutical giants like Pfizer and Johnson & Johnson pledged over $350 billion for U.S. manufacturing, while President Trump's proposed 100% tariff on branded pharmaceuticals aims to boost local production amid rising global trade tensions.

1 of 2

Story summary

President Trump will impose a 100% tariff on branded pharmaceuticals starting October 1, 2025, unless companies invest in U.S. manufacturing.
Pfizer aims to reduce drug costs and invest $70 billion domestically, supporting Trump's focus on local production.
The auto industry disputes claims of new factory construction, stating companies are retooling existing plants.
Major pharmaceutical firms, including Johnson & Johnson and Eli Lilly, have pledged over $350 billion to U.S. manufacturing due to tariff threats.
Critics caution that immediate tariffs may harm smaller biotech firms and stifle innovation, potentially aiding China's biotech sector.

1 / 2